Report
Qlife Holding AB
Redaregatan 48
HELSINGBORG, 252 36  Sweden Ticker: QLIFEQLIFE

Qlife to increase decentralized testing of professional football in Denmark with Divisionsforeningen - Egoo.Health-platform placed in three clubs


Qlife will assist professional football in Denmark to perform additional and decentralized testing of COVID-19. Weekly testing of all players and staff in league clubs has been performed since May. Now, Divisionsforeningen has decided to increase decentralized PCR-testing onsite for all clubs as a complement to the lab testing by placing the Egoo.Health-platform in three strategically located football clubs. The Egoo.Health-platform will be in place no later than December 7.

Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark. The test capacity includes weekly testing of all players and staff in league clubs in order to decrease the risk of infection spread. Divisionsforeningen is very pleased with the test capacity overall and want to initiate decentralized PCR-testing onsite with this new initiative with the Egoo.Health-platform. The clubs where the system will be placed are Brøndby, Vejle and Randers. Test results will be available in 30 minutes.

Given that the Egoo.health platform is yet not CE-marked the procedure will be done under a Qlife protocol as a performance evaluation study. The Scope is to evaluate how well the Egoo.Health platform performs in a decentralized setting at the local clubs. The study will be conducted in collaboration with Divisionsforeningen and is not part of the CE-mark proceedings, which are running in parallel.

"Divisionsforeningen is a fore runner for testing for COVID-19 among professional sport clubs in Europe. They have tested players and staff to a greater extent than is required and we have delivered tests according to protocol. The decision by Divisionsforeningen to initiate onsite PCR-testing at three individual clubs as well as a performance evaluation study is a confirmation of the success of our ongoing mission. The study will provide invaluable direct user feedback from the individual clubs on the performance of our Egoo.Health platform", says Thomas Warthoe", CEO Qlife.

Procedures//Protocol of Decentralized testing with The Egoo.Health-platform

· PRC-test with test results within 30 minutes.
· Each individual football club can perform the swab and take it to one of the test locations and perform the test by themselves.
· Each club will train and dedicate authorized personnel that is allowed to perform the test, thus making them independent of external personnel.
· Each club can perform testing 24/7.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.health (https://www.egoo.health/), Qlifeholding.com (https://qlifeholding.com/en) or follow us on LinkedIn (https://www.linkedin.com/company/28967666/).

https://news.cision.com/qlife-holding-ab/r/qlife-to-increase-decentralized-testing-of-professional-football-in-denmark-with-divisionsforeningen,c3245775

Related Businesses
- - Customer
Copyright © 2024 by CreditRiskMonitor.com (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by CreditRiskMonitor.com, Inc. Except as expressly permitted by CreditRiskMonitor.com, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that CreditRiskMonitor.com, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of CreditRiskMonitor.com, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by CreditRiskMonitor.com, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of CreditRiskMonitor.com, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable.  CreditRiskMonitor.com, Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement. 
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Thursday, April 25, 2024